Splenic Non-Hodgkin Lymphoma — Trials

Splenic Non-Hodgkin Lymphoma — Trials · CancerIndex

Clinical trials

Registered studies

166 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.

Active: 17
Recruiting: 7
Ph III recruiting: 0
Growth YoY: —
Industry share: 12%
Top sponsor: City of Hope Medical Center
Termination share: 35.9%

Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancers Terminated studies (38)

clinicaltrialsPublishedShowing 1–8 of 8 studies matching the filters · status and phase as posted by the registrant; each row links to the study record.

NCT	Title	Status	Phase	Enrollment (n)	Sponsor	Countries	Last update	Source
NCT07583810	Non-covalent BTK Inhibitor Nemtabrutinib in Combination With the CD20 Monoclonal Antibody Rituximab for the Treatment of Marginal Zone Lymphoma	recruiting	Phase 2	35	City of Hope Medical CenterOTHER	1	Sep 29, 2026	clinicaltrials
NCT07055477	A Phase I Trial Anti-CC Chemokine Receptor 4 Chimeric Antigen Receptor T Cells (CCR4 CAR T Cells) for CCR4 Expressing T-cell Malignancies Including Peripheral T-cell Non-Hodgkin Lymphoma (PTCL) and Cutaneous T-cell Non-Hodgkin Lymphoma (CTCL)	recruiting	Phase 1	60	National Cancer Institute (NCI)NIH